Independent Research Analysts Give MorphoSys (ETR:MOR) a €119.00 Price Target

Independent Research set a €119.00 ($138.37) price objective on MorphoSys (ETR:MOR) in a research note released on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently issued reports on MOR. Barclays set a €110.00 ($127.91) price target on MorphoSys and gave the stock a neutral rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. reissued a buy rating on shares of MorphoSys in a research report on Thursday, March 19th. Deutsche Bank set a €129.00 ($150.00) price target on MorphoSys and gave the stock a buy rating in a research report on Tuesday, March 3rd. Berenberg Bank set a €150.00 ($174.42) price target on MorphoSys and gave the stock a buy rating in a research report on Wednesday, February 5th. Finally, Goldman Sachs Group reissued a neutral rating on shares of MorphoSys in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of Buy and an average target price of €122.88 ($142.88).

MOR opened at €91.65 ($106.57) on Monday. MorphoSys has a 12-month low of €79.70 ($92.67) and a 12-month high of €146.30 ($170.12). The company has a current ratio of 7.80, a quick ratio of 7.63 and a debt-to-equity ratio of 9.78. The business’s fifty day simple moving average is €100.32 and its 200-day simple moving average is €108.25. The company has a market capitalization of $2.90 billion and a price-to-earnings ratio of -30.13.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Featured Story: How to calculate the intrinsic value of a stock

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.